Founded in 2018, by Ned Waller, MD, PhD, FACP, Cambium Oncology’s first-in-class antagonist blocks VIP signaling to reestablish immune surveillance and defeat cancers.

Cambium Oncology is developing first-in-class immunotherapies targeting neuroimmune checkpoints, including ANT308 and CAMV-01, antagonists of the VIP/VPAC axis. Our company was founded on intellectual property licensed from Emory University.

Checkpoint therapy fails in 70% of cancer patients not because the T-cell checkpoint is intact, but because VIP — secreted by tumor cells — silences T-cells before they can be reinvigorated. We block that suppression with a first-in-class VIP-receptor antagonist.

Our CAMV-01 dismantles 3 key pillars of tumor immune evasion: (1) myeloid immunosuppression, (2) T cell exclusion & (3) repolarizing macrophages toward an M1 phenotype and enabling cytotoxic T cell infiltration.

We’ve built a clear de-risking strategy: robust preclinical proof-of-concept, early pharmacodynamic biomarkers, and careful safety monitoring given VIP’s role in immune regulation.